secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2025-10-14T23:59:59+00:00
Accession:  0001193125-25-238065
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa appoints Mark Daniel as CFO to lead finance for commercial readiness
---------------------------------------------------------------------------

- Mark Daniel appointed CFO effective Oct 14; Heather Rees transitions to non-officer employee through Nov 15.
- Daniel receives $415,900 base salary, 40% target bonus, and 578,000-share stock option grant vesting over 4 years.
- Daniel brings 25+ years life-science finance; previously SVP Finance at Bruker Spatial Biology until 2025.
- He has managed $400M cash portfolio and executed ~$1B in equity/debt transactions, supporting Atossa's commercial launch of (Z)-endoxifen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000119312525238065/0001193125-25-238065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000119312525238065/atos-20251014.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-238065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer